PVDF/sirolimus topical
Term · Oncology and biomedicine · MLC-T-ONC-016304
A topical formulation consisting of a polyvinylidene fluoride (PVDF) polymer resin containing the macrolide sirolimus (rapamycin), produced by the organism Streptomyces hygroscopicus, with immunosuppressive activity. Upon application of topical PVDF/sirolimus, sirolimus migrates from the PVDF polymer resin into the skin. Once inside cells, sirolimus binds to the immunophilin FK binding protein-12 (FKBP-12) and forms a sirolimus:FKBP-12 complex. This complex binds to and inhibits the activity of the serine/threonine kinase mammalian target of rapamycin (mTOR), which may result in the suppression of cytokine-driven T-cell activation and proliferation.
| Identifier | MLC-T-ONC-016304 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | topical PVDF/rapamycin |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-016304",
"term": "PVDF/sirolimus topical",
"field": "Oncology and biomedicine",
"definition": "A topical formulation consisting of a polyvinylidene fluoride (PVDF) polymer resin containing the macrolide sirolimus (rapamycin), produced by the organism Streptomyces hygroscopicus, with immunosuppressive activity. Upon application of topical PVDF/sirolimus, sirolimus migrates from the PVDF polymer resin into the skin. Once inside cells, sirolimus binds to the immunophilin FK binding protein-12 (FKBP-12) and forms a sirolimus:FKBP-12 complex. This complex binds to and inhibits the activity of the serine/threonine kinase mammalian target of rapamycin (mTOR), which may result in the suppression of cytokine-driven T-cell activation and proliferation.",
"synonyms": [
"topical PVDF/rapamycin"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/pvdf-sirolimus-topical/"
}
Record 13,896 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.